Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Tuftsin Selank 10MG

Selank

Selank is a synthetic heptapeptide analog derived from the endogenous immunopeptide tuftsin, designed to enhance stability and extend biological activity while remaining non-hormonal and non-sedating. In scientific research, Selank is widely utilized as a neuropeptide research compound for investigating central nervous system signaling, neuroimmune interactions, and peptide-mediated modulation of neurotransmitter systems under controlled experimental conditions.*

Originally developed and studied within neuropharmacology and neurochemistry research, Selank is frequently referenced in studies exploring anxiolytic-like signaling pathways, stress-response mechanisms, and peptide regulation of GABAergic and serotonergic systems. Its short amino acid sequence and resistance to enzymatic degradation make it a reliable tool for reproducible laboratory research.*

  • Peptide Name: Selank
  • Peptide Class: Synthetic tuftsin-derived neuropeptide analog
  • Amino Acid Length: 7 amino acids
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)
— each
— each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

Selank

Scientific & Research Context

In published scientific literature, Selank has been investigated for its role in neuropeptide signaling related to anxiety modulation, stress adaptation, and cognitive processes in experimental models.* Research has explored Selank’s influence on GABA receptor activity, monoamine neurotransmitter balance, and expression of genes involved in synaptic plasticity and immune regulation.*

Within laboratory research settings, Selank has been utilized to study:*

  • Neuropeptide regulation of anxiety- and stress-related signaling pathways*
  • GABAergic and serotonergic neurotransmission modulation*
  • Neuroimmune interactions and cytokine-related signaling*
  • Peptide effects on cognitive and behavioral models*
  • Structure–activity relationships of tuftsin-derived peptides*

Due to its non-sedating profile and lack of hormonal activity, Selank is often selected for mechanistic studies focused on CNS modulation without confounding endocrine effects.*

Quality & Analytical Assurance

Each batch of Selank is synthesized using validated solid-phase peptide synthesis protocols and undergoes comprehensive analytical testing to confirm molecular identity, sequence integrity, and purity. Verification by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) ensures batch-to-batch consistency, reliability, and reproducibility for research applications.

Storage & Handling

Selank is supplied as a lyophilized powder to maximize stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow standard laboratory peptide protocols to preserve molecular integrity and minimize degradation.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Ashmarin, I. P., Nezavibat’ko, V. N., Levitskaya, N. G., et al. “Selank: A New Anxiolytic Peptide with Selective Activity on Behavior and the Immune System.” Neuroscience and Behavioral Physiology, 2005.
  • Ashmarin, I. P., Kamenskii, A. A., Levitskaya, N. G., et al. “Selank: A Synthetic Peptide with Anxiolytic Properties.” Bulletin of Experimental Biology and Medicine, 2008.
  • Medvedeva, E. V., Dmitrieva, V. G., Limborska, S. A., Myasoedov, N. F. “The Effect of Selank on Gene Expression in the Rat Brain.” Bulletin of Experimental Biology and Medicine, 2010.
  • Myasoedov, N. F., Andreeva, L. A. “Neuropeptides of the Tuftsin Family: Selank and Its Biological Effects.” Neurochemical Journal, 2012.
  • Zozulya, A. A., Gabaeva, M. V., Sokolov, O. Y., Surkina, I. D., Kost, N. V. “The Effects of Selank on Immune System Parameters.” Journal of Peptide Science, 2008.
  • Seredenin, S. B., Voronin, M. V., Yarkova, M. A. “Anxiolytic Properties of Selank in Experimental Models.” Experimental and Clinical Pharmacology, 2010.
  • Myasoedov, N. F., Shram, S. I. “Regulatory Neuropeptides in Stress and Anxiety: Mechanisms of Selank Action.” Neuroscience and Behavioral Physiology, 2014.
  • Medvedeva, E. V., Grivennikov, I. A., Myasoedov, N. F. “Selank Modulates GABAergic and Serotonergic Neurotransmission.” Neurochemical Research, 2013.
  • Ashmarin, I. P., Myasoedov, N. F. “Neuropeptide Regulation of Emotional and Cognitive Processes: Selank as a Model Compound.” Progress in Neurobiology, 2016.
  • Andreeva, L. A., Ivanova, E. A., Myasoedov, N. F. “Selank as a Modulator of Neuroimmune Interaction.” Bulletin of Experimental Biology and Medicine, 2017.
  • Volkova, A. et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology, 2016.
  • Kasian, A. et al. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural Neurology, 2017.
  • Zozulya, A. A. et al. “The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity.” Bulletin of Experimental Biology and Medicine, 2001.
  • Sokolov, O. Y., Meshavkin, V. K., Kost, N. V., Zozulya, A. A. “Effects of Selank on Behavioral Reactions and Enkephalin-Degrading Enzyme Activity.” Bulletin of Experimental Biology and Medicine.
  • Uchakina, O. N. et al. “Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008.
  • Zozulia, A. A. et al. “Efficacy and Possible Mechanisms of Action of Selank in Generalized Anxiety Disorders and Neurasthenia.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008.
  • Kolomin, T., Shadrina, M., Andreeva, L., Slominsky, P., Limborska, S., Myasoedov, N. “Expression of Inflammation-Related Genes in Mouse Spleen Under Selank.” Regulatory Peptides, 2011.
  • Semenova, T. P., Kozlovskiĭ, I. I., Zakharova, N. M., Kozlovskaia, M. M. “Experimental Optimization of Learning and Memory Processes by Selank.” Eksperimental’naya i Klinicheskaya Farmakologiya, 2010.
  • Kolomin, T. A. et al. “Selank-Induced Regulation of Higher Nervous Activity.” Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I.P. Pavlova, 2013.
  • Semenova, T. P. et al. “Effect of Selank on Cognitive Processes After Early Catecholaminergic System Damage.” Bulletin of Experimental Biology and Medicine.
  • Kost, N. V. et al. “Semax and Selank Inhibit Enkephalin-Degrading Enzymes from Human Serum.” Bioorganic Chemistry, 2001.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.